Tekmira Presents LNP Technology Innovations at Scientific Symposium

Tekmira Presents LNP Technology Innovations at Scientific Symposium

Highlights Include Advancements in LNP Potency, Lyophilization, and
Subcutaneous Administration

VANCOUVER, British Columbia, May 15, 2013 (GLOBE NEWSWIRE) -- Tekmira
Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of
RNA interference (RNAi) therapeutics, announced that data demonstrating its
ongoing lipid nanoparticle (LNP) technology innovations and manufacturing
related advancements were presented at the 15th Annual TIDES Summit:
Oligonucleotide and Peptide® Therapeutics from Research through
Commercialization taking place in Boston, MA today.

"We are excited about the progress being made by Tekmira scientists, who are
leading the continued innovation of LNP delivery to enable the field of RNAi
therapeutics. Tekmira's presentation at the TIDES Summit highlights some of
the recent innovations we have made surrounding our LNP technology platform,
such as industry-leading LNP potency and new lyophilized formulations that
maintain the potency of the liquid formulations. In addition, we are
presenting data for the first time with formulations administered
subcutaneously that further demonstrate our leadership in enabling RNAi
therapeutics," said Dr. Mark J. Murray, Tekmira's President and CEO.

TKM-Ebola, an anti-Ebola viral therapeutic, is being developed under a
contract with the U.S. Department of Defense's (DoD) Joint Project Manager
Transformational Medical Technologies (JPM-TMT) Office, with a total contract
value of approximately $140 million. Earlier preclinical studies were
published in the medical journal The Lancet and demonstrated that when siRNA
targeting the Ebola virus and delivered by Tekmira's LNP technology were used
to treat previously infected non-human primates, the result was 100 percent
protection from an otherwise lethal dose of Zaire Ebola virus (Geisbert et
al., The Lancet, Vol 375, May 29, 2010).

Tekmira's productive collaboration with the JPM-TMT was recently modified and
expanded to include significant advances in LNP formulation technology since
the initiation of the program in 2010. Some of the innovations highlighted in
Tekmira's session at the TIDES Summit include:

  oA new formulation, more potent than any LNP currently in clinical trials,
    is being incorporated into the TKM-Ebola program. This new TKM-Ebola LNP
    formulation has demonstrated significant increases in potency in non-human
    primates infected with the Zaire Ebola virus. At 0.5 mg/kg, 100% of the
    infected animals survived after receiving TKM-Ebola daily for seven days.
    The previous LNP formulation provided the same level of protection and
    100% survival at 2 mg/kg.
  oTekmira scientists have developed a lyophilized (freeze-dried) LNP to
    eliminate cold-chain requirements and facilitate use in tropical climates.
    Importantly, the lyophilized LNP formulation also provided 100% survival
    in non-human primates infected with the Zaire Ebola virus with no loss in
    potency at 0.5 mg/kg dosed daily for seven days. At 0.2 mg/kg, 67% of
    infected non-human primates survived.
  oTekmira has also been working on LNP formulations that can provide
    significant potency when administered subcutaneously. Tekmira presented
    data demonstrating that LNP administered subcutaneously in a rodent model
    can knockdown a liver target by 96% at 1.0 mg/kg with a single
    administration or 67% knockdown at 0.5 mg/kg after a single
    administration. Tekmira believes this potent knockdown in the liver after
    subcutaneous administration compares favorably to other published data
    using conjugate delivery systems.

Tekmira continues to build upon its leadership position and invest in its RNAi
technologies by making advancements in LNP potency, tolerability,
biodistribution, targeting, process development, and manufacturing, as well as
the evaluation of new RNAi payloads. These LNP innovations will support the
advancement of multiple RNAi therapeutics — from both Tekmira and its partners
— that address a wide variety of disease indications.


JPM-TMT is a component of the U.S. Department of Defense's Joint Program
Executive Office for Chemical and Biological Defense (JPEO-CBD). JPM-TMT aims
to protect the Warfighter from emerging infectious diseases, genetically
altered, and unknown biological threats. Through strategic investments and
partnerships with innovative biotech firms, pharmaceutical corporations, other
government agencies, and academic institutions, JPM-TMT facilitates the
advanced development and acquisition of adaptable platform technologies,
broad-spectrum medical countermeasures, and innovative systems to enhance our
nation's biodefense response capability. For more information, visit

About RNAi and Tekmira's LNP

RNAi therapeutics have the potential to treat a broad number of human diseases
by "silencing" disease causing genes. The discoverers of RNAi, a gene
silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for
Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery
technology to be effective systemically. Tekmira believes its LNP technology
represents the most widely adopted delivery technology for the systemic
delivery of RNAi therapeutics. Tekmira's LNP platform is being utilized in
multiple clinical trials by both Tekmira and its partners. Tekmira's LNP
technology (formerly referred to as stable nucleic acid-lipid particles or
SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles
that are effective in delivering RNAi therapeutics to disease sites in
numerous preclinical models. Tekmira's LNP formulations are manufactured by a
proprietary method which is robust, scalable and highly reproducible, and
LNP-based products have been reviewed by multiple FDA divisions for use in
clinical trials. LNP formulations comprise several lipid components that can
be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on
advancing novel RNAi therapeutics and providing its leading lipid nanoparticle
delivery technology to pharmaceutical partners. Tekmira has been working in
the field of nucleic acid delivery for over a decade and has broad
intellectual property covering LNPs. Further information about Tekmira can be
found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" or "forward-looking
information" within the meaning of applicable securities laws (collectively,
"forward-looking statements"). Forward-looking statements are generally
identifiable by use of the words "believes," "may," "plans," "will,"
"anticipates," "intends," "budgets," "could," "estimates," "expects,"
"forecasts," "projects" and similar expressions, and the negative of such
expressions. Forward-looking statements in this news release include
statements about Tekmira's strategy, future operations, clinical trials,
prospects and the plans of management; RNAi (ribonucleic acid interference)
product development programs; the effects of Tekmira's products on the
treatment of infectious disease, including the Zaire Ebola virus; the veracity
of recent innovations to Tekmira's LNP technology platform; the modifications
to the TKM-Ebola contract with the U.S. DoD's JPM-TMT to integrate recent
advancements in LNP formulation and manufacturing technology; and, the quantum
and timing of funding that may be provided to Tekmira pursuant to the
TKM-Ebola contract with the U.S. DoD's JPM-TMT.

With respect to the forward-looking statements contained in this news release,
Tekmira has made numerous assumptions regarding, among other things: LNP's
status as a leading RNAi delivery technology; the effectiveness of Tekmira's
products as a treatment for cancer, infectious disease, including the Ebola
Zaire virus, or other diseases; the developmental milestones and approvals
required to trigger funding for TKM-Ebola from the JPM-TMT; results in
preclinical models are indicative of the potential effect in humans; Tekmira's
research and development capabilities and resources; FDA approval with respect
to commencing clinical trials; the timing and obtaining of regulatory
approvals for Tekmira's products; the timing and results of clinical data
releases and use of LNP technology by Tekmira's development partners and
licensees; the time required to complete research and product development
activities; the timing and quantum of payments to be received under contracts
with Tekmira's partners including the DoD, and others; Tekmira's financial
position and its ability to execute on its business strategy; and Tekmira's
ability to protect its intellectual property rights and not to infringe on the
intellectual property rights of others. While Tekmira considers these
assumptions to be reasonable, these assumptions are inherently subject to
significant business, economic, competitive, market and social uncertainties
and contingencies.

Additionally, there are known and unknown risk factors which could cause
Tekmira's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements contained herein. Known risk factors
include, among others: Tekmira's research and development capabilities and
resources may not meet current or expected demand; Tekmira's products may not
prove to be effective in the treatment of cancer, infectious disease,
including the Zaire Ebola virus, or other diseases; Tekmira may not obtain and
protect intellectual property rights, and operate without infringing on the
intellectual property rights of others; Tekmira may face competition from
other pharmaceutical or biotechnology companies and the possibility that other
organizations have made advancements in RNAi delivery technology that Tekmira
is not aware of; pre-clinical and clinical trials may be more costly or take
longer to complete than anticipated and may not generate results that warrant
future development of the tested drug candidate; the FDA may determine that
the design and planned analysis of Tekmira's clinical trials do not adequately
address the trial objectives in support of Tekmira's regulatory submissions;
the FDA may not approve the commencement of Tekmira's planned clinical trials
or approve the use of Tekmira's products; the DoD may reduce or cancel certain
defense spending, including Tekmira's contract to develop TKM-Ebola; the FDA
refuse to approve TKM-Ebola, or place restrictions on our ability to
commercialize TKM-Ebola; Tekmira may not complete the work necessary for the
submission of the new LNP formulation for TKM-Ebola to the FDA in the
anticipated timeframe, or at all; Tekmira may not initiate a new TKM-Ebola
Phase I clinical trial in the anticipated timeframe, or at all; Tekmira's
development partners and licensees conducting clinical trial, development
programs and joint venture strategic alliances may not result in expected
results on a timely basis, or at all; anticipated payments under contracts
with Tekmira's collaborative partners may not be received by Tekmira on a
timely basis, or at all, or in the quantum expected by Tekmira; payments
received from third parties may not be sufficient to fund Tekmira's continued
business plan as currently anticipated; future operating results are uncertain
and likely to fluctuate; Tekmira may not be able to raise additional financing
required to fund further research and development, clinical studies, and
obtain regulatory approvals, on commercially acceptable terms or at all;
economic and capital market conditions; Tekmira may become subject to product
liability or other legal claims for which Tekmira has made no accrual in its
financial statements; Tekmira's cash runway may not extend into 2015 as
anticipated, and may be substantially less than required to continue current
operations; and the possibility that Tekmira may not have sufficiently
budgeted for expenditures necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira
appears in Tekmira's annual report on Form 20-F for the year ended December
31, 2012 (Annual Report), which is available at www.sedar.com or at
www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified
in their entirety by this cautionary statement, and Tekmira disclaims any
obligation to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or developments,
except as required by law.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com
         David Ryan
         Longview Communications Inc.
         Phone: 416-649-8007
         Email: dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo
Press spacebar to pause and continue. Press esc to stop.